Amylyx Pharmaceuticals Inc’s filing revealed that its Co-Chief Executive Officer Klee Justin B. unloaded Company’s shares for reported $30202.0 on Jan 06 ’25. In the deal valued at $4.04 per share,7,471 shares were sold. As a result of this transaction, Klee Justin B. now holds 3,176,788 shares worth roughly $11.12 million.
Then, Cohen Joshua B sold 7,471 shares, generating $30,232 in total proceeds. Upon selling the shares at $4.05, the Co-Chief Executive Officer now owns 3,213,098 shares.
Before that, Bedrosian Camille L sold 5,421 shares. Amylyx Pharmaceuticals Inc shares valued at $30,007 were divested by the Chief Medical Officer at a price of $5.54 per share. As a result of the transaction, Bedrosian Camille L now holds 138,380 shares, worth roughly $0.48 million.
Robert W. Baird upgraded its Amylyx Pharmaceuticals Inc [AMLX] rating to an Outperform from a a Neutral in a research note published on November 18, 2024; the price target was increased to $11 from $3. A number of analysts have revised their coverage, including BofA Securities’s analysts, who increased its forecast for the stock in late October from “a Neutral” to “a Buy”. Mizuho also remained covering AMLX and has decreased its forecast on March 18, 2024 with a “Neutral” recommendation from previously “Buy” rating. Robert W. Baird revised its rating on March 11, 2024. It rated AMLX as “a Neutral” which previously was an “an Outperform”.
Price Performance Review of AMLX
On Friday, Amylyx Pharmaceuticals Inc [NASDAQ:AMLX] saw its stock fall -7.16% to $3.50. Over the last five days, the stock has lost -10.49%. Amylyx Pharmaceuticals Inc shares have fallen nearly -7.41% since the year began. Nevertheless, the stocks have fallen -78.66% over the past one year. While a 52-week high of $19.95 was reached on 01/03/25, a 52-week low of $1.58 was recorded on 01/10/25. SMA at 50 days reached $4.91, while 200 days put it at $2.99.
Levels Of Support And Resistance For AMLX Stock
The 24-hour chart illustrates a support level at 3.36, which if violated will result in even more drops to 3.23. On the upside, there is a resistance level at 3.71. A further resistance level may holdings at 3.93. The Relative Strength Index (RSI) on the 14-day chart is 32.44, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.21, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 91.89%. Stochastics %K at 14.78% indicates the stock is a buying.
How much short interest is there in Amylyx Pharmaceuticals Inc?
A steep rise in short interest was recorded in Amylyx Pharmaceuticals Inc stocks on 2024-12-13, growing by 39290.0 shares to a total of 1.57 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 1.53 million shares. There was a rise of 2.51%, which implies that there is a positive sentiment for the stock.
